Phase 3 RCT in 40,703 adults aged ≥50: mRNA-1010 influenza vaccine vs licensed standard-dose vaccine had fewer RT-PCR-confirmed influenza-like illnesses (2.0% v 2.8%; relative efficacy 26.6%), meeting superiority. Solicited reactions were more frequent with mRNA-1010.
RCTn = 40,703
Leroux-Roels et al. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults